Abstract
Objective:To evaluate the clinical effects of apatinib combined with DOS regimen in the neoadjuvant chemotherapy for locally advanced gastric cancer (LAGC).Methods:Eighty patients with LAGC admitted to Baoding first Central Hospital from January 2018 to October 2020 were randomly divided into two groups (n=40, respectively). The control group received DOS chemotherapy regimen alone. The experiment group additionally orally took apatinib mesylate tablets. The changes in CEA, CA19-9 and other tumor markers, RO resection rate, incidence of operative complications, adverse reactions, and other indicators were compared between the two groups.Results:The overall response rate (ORR) of the experimental group was 72.5%, which was significantly better than that of the control group (50%) (p=0.03). After the treatment, the CEA and CA19-9 in the experiment group were significantly lower than those in the control group (p=0.00). The Ro resection rate was 77.5% in the experiment group and 57.5% in the control group (p=0.03). The operation time was shortened and amount of bleeding decreased in the experiment group, and the differences were statistically significant (p=0.00). The incidence of surgical complications in the experimental group was 17.5%, significantly lower than that in the control group (37.5%) (p=0.04).Conclusion:Apatinib combined with DOS regimen is effective for patients with LAGC without significantly increasing adverse reactions. Meanwhile, tumor markers are reduced significantly. Besides, the Ro resection rate and the incidence of operative complications are obviously superior to the DOS neoadjuvant chemotherapy regimen alone.
Highlights
Gastric cancer (GC) is one of the most common malignant tumors of digestive tract.[1]
It suggested that the overall response rate (ORR) was 72.5% in the experiment group and 50% in the control group
The results showed that the 5-year survival rate and radical operation (Ro) resection rate in patients underwent operative treatment after neoadjuvant chemotherapy were significantly higher than those in patients receiving operative treatment alone, and the differences were statistically significant
Summary
Gastric cancer (GC) is one of the most common malignant tumors of digestive tract.[1] Its morbidity and mortality rate rank the 2nd among malignant tumors throughout the world. Its early onset is insidious; and the symptoms lack specificity. Some patients are at the middle and advanced stages when confirmed, losing the optimal treatment period.[2] GC patients are characterized with low radical operation (Ro) resection rate and high mortality rate.[3]. More and more clinical studies have shown that, neoadjuvant chemotherapy can improve the overall survival (OS) of patients, and
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
